Source comparison
Compounded Sermorelin vs FDA-Approved Medications
Compounded sermorelin prepared by 503B outsourcing facilities is not the same as an FDA-approved drug product, but it's also not 'unregulated'. Section 503B of the Federal Food, Drug, and Cosmetic Act establishes FDA oversight for large-scale compounding opera
This comparison does not assign a generated winner or score.
- Compounded sermorelin prepared by 503B outsourcing facilities is not the same as an FDA-approved drug product, but it's also not 'unregulated'. Section 503B of the Federal Food, Drug, and Cosmetic Act establishes FDA oversight for large-scale compounding operations that ship across state lines. These facilities must register with the FDA, undergo biennial inspections, report adverse events, and follow current Good Manufacturing Practices (cGMP). What they don't do: conduct Phase III randomized controlled trials or submit New Drug Applications (NDAs) for each compound they prepare.
- The distinction matters for patient expectations around purity, potency, and traceability. FDA-registered 503B facilities like those supplying Real Peptides batch-test sermorelin acetate for sterility, endotoxin levels, and amino acid sequence accuracy using HPLC and mass spectrometry. Results are documented in Certificates of Analysis (CoAs) available on request. What's absent: the multi-site Phase III trial data demonstrating long-term safety and efficacy that branded medications carry. Compounded sermorelin relies on the base FDA approval for diagnostic use plus decades of clinical observation in off-label contexts. Not formal therapeutic trial validation.
- Does that make it unsafe? No. Does it change the legal and evidentiary framework? Yes. Patients using compounded sermorelin are relying on prescriber judgment and compounding pharmacy quality controls rather than manufacturer-backed clinical trial endpoints.